Clinical News
Bladder Cancer News
Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (April 3, 2018)CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading
Keytruda Improves Survival of Advanced Bladder Cancer (February 26, 2018)CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary... Continue Reading
Avelumab Immunotherapy Approved for Bladder Cancer (May 15, 2017)Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading
FDA Approves Imfinzi for Treatment of Urothelial Cancer (May 11, 2017)The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading
FDA Approves Opdivo for Treatment of Bladder Cancer (February 16, 2017)The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading
Tecentriq® Approved for Bladder Cancer (June 8, 2016)The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading
Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading
Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (March 14, 2016)Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading
Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer (January 21, 2016)The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium... Continue Reading
Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading
Latest Bladder Cancer News By Stage
Recurrent Bladder Cancer
Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)
The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading
Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading
Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading
Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading
Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading
More Recurrent Bladder CancerScreening/Prevention Bladder Cancer
Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)
Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading
More Evidence that Diabetes Drugs Increase Risk of Bladder Cancer (August 22, 2012)A popular class of diabetes drugs called thiazolidinediones (TZDs) increases the risk of bladder cancer, according to the results of a study published early online in the Journal of the National Cancer Institute. Bladder cancer is diagnosed in as many... Continue Reading
Diabetes Drugs May Increase Risk of Bladder Cancer (July 26, 2012)A class of drugs called thiazolidinediones has been linked to an increased risk of bladder cancer among adults with type 2 diabetes, according to a study published early online in the Canadian Medical Association Journal. Bladder cancer is diagnosed... Continue Reading
Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading
Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading
More Screening/Prevention Bladder CancerStage III Bladder Cancer
Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)
Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading
Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading
Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading
Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading
Study Explores New Approach to Boosting the Immune System after Cancer Treatment (August 24, 2011)Researchers are seeking participants for a Phase II clinical trial that will explore whether an investigational treatment can help the immune system recover after cancer treatment. Cancer treatments such as chemotherapy and radiation therapy often deplete... Continue Reading
More Stage III Bladder CancerStage IV/Metastatic Bladder Cancer
Tecentriq® Approved for Bladder Cancer (June 8, 2016)
The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading
Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading
Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading
Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading
Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading
More Stage IV/Metastatic Bladder CancerStages 0-I Bladder Cancer
Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)
The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading
Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading
Study Compares Two Types of BCG for Bladder Cancer (April 10, 2012)For non-muscle-invasive bladder cancer, use of theConnaughtstrain of bacillus Calmette-Guérin (BCG) may be more effective at preventing recurrences than the Tice strain of BCG. These results—from a Phase III clinical trial—were presented at the 2012... Continue Reading
More Stages 0-I Bladder CancerStages II-III Bladder Cancer
Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)
The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading
Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading
Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading
Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading
Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading
More Stages II-III Bladder Cancer